EQT makes unsolicited all-cash takeover offer for British biotech firm Oxford Biomedica

British cell and gene therapy manufacturer Oxford Biomedica plc OXB.Lconfirmed on January 14, 2026, that it has received an unsolicited all-cash acquisition proposal from investment firm EQT. The company, which provides pharmaceutical contracting services from its base in the United Kingdom GB, is currently engaging in preliminary discussions regarding the potential offer.\n\nThis latest approach follows previous unsolicited proposals from EQT that were rejected by Oxford Biomedica plc. Under takeover rules in the United Kingdom, the potential acquirer now has a firm deadline of February 11, 2026, to either announce a firm intention to make an offer or formally withdraw from the process.\n\nOxford Biomedica plcplays a significant role in the biotechnology sector as a specialist provider of services for advanced therapies.

For the six months ended June 30, 2025, the company reported total revenue of 73.2 million pounds, which is approximately 98.40 million dollars, reflecting its operational scale in the United Kingdom.\n\nThe company has stated that these preliminary talks may or may not lead to a formal offer. At this stage, Oxford Biomedica plc continues to fulfill its contracting obligations for pharmaceutical clients while the board evaluates the strategic implications of the proposal ahead of the February deadline.